Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
None
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.

  • 56 views
  • 16 Jul, 2021
  • 18 locations
None
SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.

  • 0 views
  • 03 Dec, 2021
  • 1 location
None
Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas

The randomized, controlled trial is aiming at comparing local control rate between two surgical resections, barrier resection and local wide resection with 1cm or equivalent normal tissues. This is based on the fact that the goal of local surgical treatment is to remove the tumor with negative margin and best …

  • 5 views
  • 08 Nov, 2020
None
Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

(dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or

neutrophil count
dedifferentiated liposarcoma
EGFR
ifosfamide
tubal occlusion
  • 0 views
  • 30 Jul, 2021
  • 23 locations
None
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1 and Cohort 2) or MRCLS (Cohort 1) .

  • 28 views
  • 26 Nov, 2021
  • 39 locations
None
Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose urothelial, head and neck, gastric (stomach), esophagogastric junction (EGJ), non-small cell lung (NSCLC), esophageal or ovarian cancer that express the MAGE-A4 protein.

esophageal cancer
esophagus cancer
sarcoma
ovarian cancer
carcinoma
  • 10 views
  • 24 Nov, 2021
  • 20 locations
None
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel GSK3377794)T-cells Specific in NY-ESO-1/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with non-small cell lung cancer.

lymphoma
pd-l1
ROS1
EGFR
lung cancer
  • 61 views
  • 10 Oct, 2021
  • 31 locations
None
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.

measurable disease
cyclophosphamide
bone marrow procedure
sarcoma
anthracyclines
  • 4 views
  • 27 Nov, 2021
  • 36 locations
None
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma.

metastasis
neutrophil count
measurable disease
liposarcoma
systemic therapy
  • 0 views
  • 02 Dec, 2021
  • 7 locations
None
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

resection is deemed to cause unacceptable morbidity or mortality) or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy.

neutrophil count
trabectedin
cancer
liposarcoma
cancer chemotherapy
  • 8 views
  • 05 Dec, 2021
  • 5 locations